WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (ProKidney or the Firm) is a number one late-stage scientific Stage Cell Therapeutics, Inc., immediately introduced the pricing of an underwritten public providing and concurrent registered direct providing of 53,719,009 shares of Class A typical inventory at a value of $2.42 per share (earlier than relevant underwriting reductions and commissions). As well as, the underwriters can have a 30-day choice to buy as much as an extra 15% of the Class A typical shares bought within the underwritten public providing. All shares of Class A typical inventory on this underwritten public providing and simultaneous registered direct issuance will probably be bought by the Firm. Topic to customary closing circumstances, the general public providing and simultaneous registered direct providing are anticipated to be accomplished on or about June 13, 2024. An underwritten public providing isn’t conditional on the closing of a concurrent direct providing, and a concurrent direct providing isn’t conditional on the closing of an underwritten public providing.
ProKidney at the moment intends to make use of the online proceeds from the underwritten public providing and concurrently registered direct providing for scientific trial bills and different analysis and growth bills, to proceed investing in its drug growth platform, for its pre-commercial and business actions, together with business manufacturing amenities, and Different normal company functions, together with working capital, capital expenditures and normal and administrative bills.
Jefferies, JP Morgan and Guggenheim Securities are performing as joint book-running managers for the proposed underwritten public providing, and PJT Companions (NYSE:) is performing as co-manager. PJT Companions can be serving as monetary advisor to the corporate in reference to the providing.
A shelf registration assertion referring to the Class A typical inventory has been filed with the SEC and declared efficient on November 30, 2023 (File No. 333-275701). A preliminary prospectus complement and accompanying prospectus referring to the underwritten public providing have been filed with the SEC and can be found on the SEC’s web site at www.sec.gov. The ultimate prospectus complement and accompanying prospectus could also be obtained on the SEC’s web site at http://www.sec.gov or by contacting Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, New York, New York 10022 , name (877) 821-7388 or e-mail Prospectus_Department@Jefferies.com; J.P. Morgan Securities LLC, c/o Broadridge Monetary Options (NYSE: ), 1155 Lengthy Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or e-mail prospectus-eq_fi@jpmchase.com; or Guggenheim Securities, LLC Attn: Fairness Syndicate Division, 330 Madison Avenue, eighth Flooring, New York, New York 10017, name (212) 518-9544, or e-mail GSEquityProspectusDelivery@guggenheimpartners.com. A preliminary prospectus complement and accompanying prospectus referring to the registered direct providing have been filed with the SEC and can be found on the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and accompanying prospectus referring to the registered direct providing could also be obtained on the SEC’s web site at http://www.sec.gov, when accessible, or by contacting the Firm at ProKidney Corp., 2000 Frontis Plaza) Blvd., Suite 250, Winston-Salem, North Carolina 27103, Attn: Bruce Culleton, MD
This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase these securities, nor shall there be any supply, solicitation or sale of those securities in any state or jurisdiction through which such supply, solicitation or sale could be illegal previous to its launch. Habits.
About ProKidney Company
ProKidney is a pioneer within the progressive remedy of persistent kidney illness via cell remedy, based in 2015 after ten years of analysis. ProKidney’s lead product candidate rilparencel (also called REACT®) is a first-in-class, proprietary autologous cell remedy that’s being evaluated for its potential to guard kidney perform in diabetic sufferers at excessive threat for kidney failure. Rilparencel has acquired Regenerative Medication Superior Remedy (RMAT) designation, in addition to FDA and EMA steering, supporting its ongoing Section 3 scientific program.
forward-looking statements
This press launch comprises sure forward-looking statements relating to ProKidney throughout the that means of the federal securities legal guidelines, together with statements relating to the timing, measurement and completion of the general public providing and simultaneous registered direct providing, and the funding awarded to the underwriters. Choice to concern extra shares, meant use of proceeds from this public providing and simultaneous registered direct providing, and different non-historical data. Precise outcomes or developments could differ materially from these projected or implied by these forward-looking statements. Elements that would trigger such variations embrace the dangers and uncertainties related to consummating an underwritten public providing and a simultaneous registered direct providing on the anticipated phrases or in any respect, market circumstances and the satisfaction of customary closing circumstances in reference to the providing. For extra details about the dangers and uncertainties confronted by ProKidney, please see the part titled “Threat Elements” within the preliminary prospectus complement filed with the SEC in reference to the general public providing and concurrent registered direct providing. Any forward-looking statements contained on this press launch converse solely as of the date of this press launch, and ProKidney disclaims any intention or obligation to replace or revise any forward-looking statements, whether or not because of new data, future occasions or in any other case.
Supply: ProKidney Company.
Investor enquiries:
Kidney-friendly
Ethan Holdaway
Ethan.Holdaway@prokidney.com
Life Sciences Consultants LLC
Daniel Ferry
daniel@lifesciadvisors.com
Supply: ProKidney
